PRJDB1903
Whole exome analysis of myelodysplastic syndromes
Whole exome analysis was performed for 29 MDS (myelodysplastic syndromes) samples, where entire exon sequences were enriched by using SureSelect Human All Exon kit (Agilent Technologies) and were subjected to resequencing analysis using Genome Analizer IIx (Illumina). More than 60% of mapped reads contained exon sequences. > 80% of exons were sequenced at the depth of >20 with average fold-coverage of  >50 times. Given that the constitutive genomic DNA was difficult to obtain in MDS patients, paired CD3-positive T cells were used as a normal control. none provided